Document is current

Article History

Received: 2 July 2024

Accepted: 5 November 2024

First Online: 20 November 2024

Declarations

:

: This work was authorized by the local ethics committees of the Valencia Clinic University Hospital (Spain) (2021/247) and of La Fe University Hospital (2022–847-1) and conducted following the Declaration of Helsinki principles.

: Informed consent was obtained from all individual participants included in the study.

: GJW reports personal fees from Quibim related to this work. He is a former employee of SOTIO Biotech Inc., and reports personal fees from Imaging Endpoints II, MiRanostics Consulting, International Genomics Consortium, Angiex, Gossamer Bio, Oncacare, Rafael Pharmaceuticals, Immunocore, Harvest Integrated Research Organization, Kymera, and SPARC-all outside this submitted work; has ownership interest in MiRanostics Consulting, Exact Sciences, Moderna, Agenus, Aurinia Pharmaceuticals, and Circulogene-outside the submitted work; and has issued patents—all outside the submitted work. AAB is the CEO and a shareholder of Quibim. AEF, AFM, AJP, APP, FBB, and JPF are current employees of Quibim. MG is consultant for Novartis, Kite, BMS, MSD and Pierre Fabre. MJT is consultant of Beigene, Gilead, F. Hoffmann-La Roche Ltd, Abbvie and Janssen; received funding from Gilead; and is member of advisory comittees on F. Hoffmann-La Roche Ltd, Janssen, Gilead, Takeda, Abbvie and Beigene. This work was partially presented at the 65th Annual Meeting of the American Society of Hematology, 2023.